Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]
Synonyms
2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid
Gemfibrozil
Gemfibrozilum
Gemfibrozilo
2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansäure
2,2-Dimethyl-5-(2,5-xylyloxy)valeriansäure
Brand Names
Apo-gemfibrozil Cap 300mg USP
PMS-gemfibrozil
Apo-gemfibrozil
Mylan-gemfibrozil
Dom-gemfibrozil
Nu-gemfibrozil Cap 300mg
PHL-gemfibrozil
Nu-gemfibrozil Tab 600mg
Scheinpharm Gemfibrozil
Penta-gemfibrozil
Gemfibrozil
Gemfibrozil-300 - Cap
Gemfibrozil-600 - Tab 600mg
Teva-gemfibrozil
Gemfibrozil Cap 300mg
Lopid
Lopid 600mg
Gemfibrozil Tab 600mg
Riva-gemfibrozil
Lopid Cap 300mg
Indication
Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions.[L8525] Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.[L8525]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
